Kiora Pharmaceuticals Inc (NASDAQ: KPRX)

Kiora Pharmaceuticals Inc. (KPRX) is a clinical-stage specialty pharmaceutical company that operates in the biotechnology industry. The company is dedicated to developing and commercializing therapies for the treatment of orphan retinal diseases.

Kiora's main business activities revolve around the research, development, and commercialization of innovative therapies for retinal diseases. The company's operations span across various countries, with a strong focus on the United States.

The company generates revenue primarily through the development and commercialization of its therapies. Its primary products include KIO-301, a small molecule photoswitch that has received orphan drug designation from the FDA for the treatment of retinitis pigmentosa (RP). KIO-301 is designed to restore vision in patients with inherited and age-related degenerative retinal diseases. The molecule is a novel small molecule that confers light sensitivity to downstream retinal ganglion cells, potentially triggering the same phototransduction signaling as if the photoreceptors were present and viable.

In addition to KIO-301, Kiora is also developing KIO-104, a third-generation small molecule dihydroorotate dehydrogenase (DHODH) inhibitor, for the treatment of posterior non-infectious uveitis. KIO-104 has been shown to be safe and well-tolerated in a Phase 1b/2a clinical trial, with a promising efficacy signal in improving inflammatory parameters and visual acuity.

Kiora's competitive advantage lies in its focus on developing innovative therapies for orphan retinal diseases. The company's partnerships with Théa Open Innovation (TOI) and other companies demonstrate its ability to collaborate and leverage the expertise of others to advance its product candidates.

In terms of customers, Kiora's products are designed to be used in a clinical setting, and its customers are likely to be based in hospitals and research institutions. They are primarily ophthalmologists and other healthcare professionals who specialize in the treatment of retinal diseases.

Kiora's brand names and/or trade names of its products and services include KIO-301, KIO-104, and KIO-101. These products are at the core of the company's business activities and are the primary drivers of its revenue. Kiora's intellectual property portfolio, built on patents, proprietary rights, trade secrets, know-how, continuing technological innovation, and in-licensing opportunities, provides a foundation for its future growth and development.